Press Releases

Latest

Second Global ISO Standard Expands LumaCyte Measurement Framework to Mammalian Cell Viability

June 2026

LumaCyte has been newly recognized in a global ISO viability standard, marking one of the most significant updates to cell viability assessment in decades. The standard incorporates LumaCyte’s label‑free optical and fluidic force approach, enabling earlier detection of functional decline and more consistent, reliable analytics for biologics and cell therapy manufacturing. This is LumaCyte’s second ISO inclusion this year, reinforcing its growing role in advancing global measurement standards.

LumaCyte Analytical Method Included in Newly Published ISO Global Standard for Viral Vector Quantification

March 2026

The newly published ISO 16921‑2:2026 standard—focused on quantification methods for viral vectors—now includes LumaCyte’s optical and fluidic force–based analytical approach, the core technology behind its Radiance® platform. This inclusion signals international validation of the method’s precision and relevance for measuring viral titers, a critical requirement in gene therapy and vaccine manufacturing.

LumaCyte Unveils Predictive CAR T DonorAnalytics to Revolutionize Cell TherapyManufacturing

September 2024

LumaCyte has launched a groundbreaking cell therapy application for predictive CAR T donor analytics using their Laser Force Cytology™ (LFC™) technology and Radiance® instrument. This innovation provides deep insights into patient and donor cellular material, predicting manufacturing success and enhancing production consistency. LumaCyte also offers a new donor qualification service, allowing customers to send samples for analysis, aiming to revolutionize cell therapy by minimizing risks and increasing yields.

LumaCyte Launches the Laser Force Cytology™ Academy after Training FDA Reviewers

July 2024

LumaCyte is launching the Laser Force Cytology™ Academy, an interactive library of training courses. This initiative aims to enhance understanding of their LFC™ technology and empower scientists and biomanufacturers in process development and production workflows.

LumaCyte Launches New Compact Radiance® Instrument for Advanced Therapy Biomanufacturing & QC Environments

October 2023

LumaCyte has launched a compact version of their Radiance® instrument, now occupying only 16 inches of bench space. The advanced Laser Force Cytology™ (LFC) technology remains unchanged, catering to space-constrained biomanufacturing facilities.

LumaCyte Fueled for Growth, Names Top Life Sciences Industry Executives to Board

March 2022

LumaCyte announces the successful completion of A round financing that will allow the company to accelerate global growth, in addition to announcing the appointmentment of two industry executives, Paul M. Meister, and Peter L. Buzy, to its Board of Directors.

LumaCyte Appoints Vaccine Manufacturing Expert to Scientific Advisory Board

April 2021

LumaCyte announces the addition of Jim Robinson to its Scientific Advisory Board (SAB). Jim brings more than 35 years of CMC vaccine manufacturing experience to the LumaCyte SAB, holding previous executive level positions at Merck, Sanofi Pasteur and Novavax.

LumaCyte Expands into Europe Tackling Expansive Vaccine and Cell and Gene Therapy Markets

February 2020

LumaCyte launches European subsidiary, LumaCyte, B.V., in the Netherlands to serve as its hub for instrument sales and service in EMEA. Having resources close to our customers is critical for maintaining outstanding customer service and support.

LumaCyte’s Laser Force Cytology Accelerating Gene Therapy Production

January 2020

LumaCyte recently collaborated with global cell and gene therapy leader, Catalent, where their joint teams uncovered valuable new capabilities in the monitoring of adeno-associated virus (AAV) production and infectivity, foundational precursors in the production of gene therapy products.

LumaCyte joins The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)

September 2017

LumaCyte joins The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), a Manufacturing USA institute sponsored by the National Institute of Standards and Technology (NIST).